Introduction
Graves' disease (GD) is the most common cause of hyperthyroidism (HT). The treatment of HT associated with GD includes administration of anti-thyroid drugs (ATDs), thyroidectomy, and radioiodine therapy (RIT) [1] . RIT is being used increasingly more often in GD treatment as it is simple, inexpensive, effective, and reliable. Administration of radioiodine (RAI) results in destruction of the overfunctioning thyroid tissue, elimination of HT with a high success rate, and in development of euthyroidism or hypothyroidism [2, 3] . However, therapy failure and increased exposure to radiation due to a second dose of RIT may pose a problem. Although the failure rate can be reduced using higher RAI doses initially, administration of higher doses of RAI may increase the radiation dose [3] [4] [5] [6] [7] . Despite the fact that this therapy has been used reliably for seven decades, there are still differing points of view with regard to determination of the appropriate dose [8] [9] [10] . Fixed RAI doses result in different outcomes in different patients, which indicates that many factors other than the administered dose affect therapy outcome [3, [11] [12] [13] . This study aims to evaluate the factors that may cause failure in GD patients who are given 10 mCi fixed-dose RAI as well as assess the predictability of treatment outcome.
Patients and methods
We conducted a retrospective study of 123 patients (M/F: 42/81) who received a single dose of RIT for HT associated with GD between 2006 and 2010 and who had regular follow-up after the therapy. GD diagnosis was confirmed with clinical, laboratory, thyroid scintigraphy, ultrasonography, and RAI uptake results in all patients. All patients had a documented relapse after anti-thyroid medication treatment. As part of administration of ATDs, 33 patients were given methimazole and 90 were given propylthiouracil (PTU) before RIT.
A fixed-dose regimen was used in the treatment of hyperthyroid patients; this study registered the patients who were given RAI at a dose of 10 mCi, which is our most commonly preferred dose in the treatment of GD. Moderate-to-severe ophthalmopathy or previous treatment with thyroidectomy were the exclusion criteria in the study.
All patients had RAI uptake measurements taken 4 and 24 h after 50 mCi RAI administration using a thyroid uptake probe. The intake of ATDs of the patients was interrupted 3 days before taking RAI uptake measurements and administering RIT. They were resumed 3 days after the therapy and gradually discontinued 1 month after therapy. In addition, the patients were started on a low-iodine diet for 10 days before the therapy. The median interval between RAI uptake measurements and RIT administrations was 12 days (range: 4-21 days). An uptake ratio (UR) was calculated by dividing 4-h iodine uptake value by 24-h iodine uptake value. Ultrasonography was used to measure the pretherapy thyroid volume using an ellipsoid model [length (cm) Â width (cm) Â depth (cm) Â 0.5248].
Patients were followed up for 1-3 months after RIT administration within the first year and for 6-9 months between the first and third years, using a questionnaire to inquire about possible symptoms of HT or hypothyroidism and thyroid function tests (free T3, free T4, thyroidstimulating hormone). The median follow-up period was 12 months (range: 12-36 months).
Patients who had hypothyroidism or euthyroidism, diagnosed on the basis of thyroid function tests, were categorized as those in whom treatment had been successful. In contrast, those who had to use ATD or who received a second dose of RIT at the end of the first year were considered as those in whom treatment had been a failure. Patients who had elevated thyroidstimulating hormone in post-therapy follow-up visits continued to be followed up for at least 6 more months to exclude the possibility of temporary hypothyroidism.
The relationship between pretherapy clinical factors, in the form of laboratory results [age, sex, BMI, type of ATD (PTU or methimazole), PTU doses, iodine uptake, UR, and thyroid volume], and treatment failure was evaluated.
Statistical analysis
All statistical analyses were carried out using SPSS version 16.0 for Windows (SPSS Inc., Chicago, Illinois, USA). The Kolmogorov-Smirnov test was used to evaluate normality of distribution for continuous variables. The t-test was used for normally distributed data and the Mann-Whitney test was used for non-normally distributed data to compare continuous variables in the two groups (patients who experienced success or failure with RIT); the w 2 -test was used to compare categorical variables. P values less than 0.05 were considered statistically significant. The odds ratio at the 95% confidence interval was calculated for patients with UR of at least 1 and compared with those with UR less than 1.
Results
This study analyzed the results of 123 GD patients who received a single fixed dose (10 mCi) of RAI in our department between 2005 and 2009. Post-RIT follow-up results showed that RIT was successful in 96 (78%) patients and failed in 27 (22%). Of the 96 patients in whom RIT was successful, 71 developed hypothyroidism and 25 developed euthyroidism. The median follow-up time periods for patients with hypothyroidism, for those with euthyroidism, for those in whom treatment failed, and for all patients taken together were 15 months (range: 12-30 months), 24 months (range: 12-36 months), 12 months (range: 12-18 months), and 12 months (range: 12-36 months), respectively. The median cure time was 3 months (range: 1-6 months). Of the 27 patients in whom RIT failed, 22 were administered a second dose of RIT. The second dose of RIT was given after a median period of 12 months (range: 9-18 months) following the first dose. Twenty patients were administered a dose of 15 mCi and two were administered a dose of 20 mCi as the second RAI dose. The median follow-up period after the administration of the second dose was 12 months (range: 9-18 months). Follow-up results after the second dose showed that, of the 22 patients, 19 (86%) developed hypothyroidism and two (9%) developed euthyroidism. The second dose therapy failed in only one patient (5%), who developed hypothyroidism after the administration of the third dose of 20 mCi.
Factors that affected cure
The effects of pretherapy clinical and laboratory factors on the failure of the first RIT dose are presented in Table 1 . No statistically significant relationship was identified between failure of RIT and age, sex, BMI, type of ATD used (PTU or methimazole), and daily PTU dose (P > 0.05).
There was a statistically significant relationship between 4-h uptake, 24-h uptake, UR, and thyroid volume and treatment failure. Four-hour uptake, 24-h uptake, UR values, and thyroid volume were significantly elevated in patients in whom RIT failed, compared with patients in whom the therapy succeeded.
It was noted that in 25 (20%) patients (17 female and eight male) who received RIT 4-h iodine uptake values were greater than or equal to 24-h iodine uptake values (UR Z 1). Baseline features of patients with UR of at least 1 and UR less than 1 have been summarized in Table 2 . RIT failed in 20 of 25 patients (80%) whose UR was at least 1, whereas RIT failed in only seven of 98 patients (7%) whose UR was less than 1. The odds ratio showed that patients with a UR value of at least 1 had a 52-fold risk for RIT failure (95% confidence interval =14.965-180.693).
Discussion
There are three options for treatment of GD, a common cause of HT: ATD, RIT, and surgery. Of these, RIT has being used more commonly in the treatment of GD as either first-line or second-line treatment for more than seven decades [1, 14] . When compared with the other two therapeutic options, RIT is the easiest to administer and the most inexpensive treatment with the fewest side effects [10, 13] . However, treatment failure, which may occur in 8-50% of cases after the first dose of RIT, still poses a problem [6,13,14].
The major parameters that determine the outcome of RIT include the iodine dose administered and the dose absorbed by the thyroid tissue [7, 15] . Although several dosimetric studies were conducted to obtain a high treatment success with the smallest dose, there is still no consensus on the optimal dose and the mode of determining the actual dose to be administered [6, [15] [16] [17] . RAI dose can be determined by using either a fixed dose or a patientspecific calculated dose. The fixed-dose approach may vary between a low and ablative dose [18, 19] . In the calculated dose regimen, the dose calculation relies on the use of two or more of the following variables: thyroid volume, thyroid uptake values, and/or RAI effective half life [15, 19, 20] . Although requiring complex dosimetric calculations and additional time, the calculated dose regimen produced treatment successes similar to those obtained with the fixed-dose regimen; therefore, nowadays many centers prefer using the simpler fixed-dose regimen [2, 3, 17, 20, 21] .
In our study, which included a homogenous group of GD patients who suffered a relapse after anti-thyroid treatment and who received a single fixed dose of 10 mCi RAI, we observed 22% treatment failure and 78% treatment success (58% hypothyroidism, 20% euthyroidism), which is consistent with other studies that used the same dose [8] . Other studies including different patient groups and using different dose regimens in the literature have reported treatment failure rates between 8 and 50% [6, 22, 23] . Although the lowest treatment failure rates were obtained using the ablative dose regimen, as higher doses are administered to patients who could be treated with lower doses, they have serious limitations, such as ignoring the ALARA principle and increasing whole-body radiation exposure [22, 23] . Besides, lower dose administrations, which could be preferred to ablative dose administrations, may result in higher rates of failure and require second and third RIT administrations more commonly. These procedures not only violate the ALARA principle but also increase whole-body exposure. That is the major reason for the uncertainty surrounding the ideal dose alternatives. In our study, 22 patients were given a second dose and one patient was given a third round of RIT because of treatment failure.
There are several studies in the medical literature exploring the risk of cancer development following radioactive iodine treatment. Some studies have found an elevated risk of stomach, kidney, and breast cancers in association with the cumulative RAI dose increase [24] . However, there are also studies involving large series that do not support this result [25] . None of the patients in our series developed any tumor of thyroidal or extrathyroidal origin throughout our short follow-up period.
Several studies were conducted to evaluate the factors that may affect the development of treatment failure and predict the patients in whom the treatment may fail. They showed correlations between treatment failure and many parameters, including turnover rate, thyroid size, biological half life, exophthalmos, uptake values, and UR All values are expressed as mean±SD for continuous variables and as the number of patients (percentage) for categorical variables. UR, uptake ratio. in RIT [3, [11] [12] [13] [14] . However, no practical method to predict outcome and reduce or prevent treatment failure was reported. In this study, we tried to evaluate the parameters that might affect outcome by comparing patients in whom the treatment had been successful with those in whom the treatment had failed. We did not find any statistically significant relationship between treatment failure and age, sex, BMI, type of ATD used, and PTU dose. However, we found that 4-and 24-h RAI uptake, UR, and thyroid volume values were higher in patients in whom therapy had failed in comparison with those in whom the treatment had been successful (P < 0.05).
The increase in thyroid iodine turnover rate in hyperthyroid patients causes RAI to be rapidly eliminated from the thyroid and its effective half life to be shortened, thus reducing the success of RAI treatment [16, [26] [27] [28] [29] [30] . Furthermore, in the presence of a rapid turnover, elevated radiolabeled thyroid hormone in the circulation of these patients increases the amount of radiation that all body organs are exposed to [7, 31] . Effective half-life measurements determine that the patients with rapid turnover may require more than 10 measurements to be taken over 7 days. However, this method is rarely used, as it is labor intensive [15, 16, 32] . UR is a simple index that can be used to identify patients with a high iodine turnover, and there are only a few studies in the literature that investigate the relationship between UR and therapy outcome [16, 26, 27] . In a study in which a calculated dose regimen was used in hyperthyroid patients [26] , UR was at least 1 in 15% of the patients in whom treatment failure was about 50%, and the failure rate in patients with a UR less than 1 was 11%. In our study we found a UR value of at least 1 in 20% of the patients. Treatment failure rate was 80% in patients with a UR value of at least 1, whereas the failure rate was only 7% in those with a UR value of less than 1.
Both our study and similar outcome studies have demonstrated that thyroid uptake and thyroid volume values are parameters that correlate with treatment failure [3, 11, 12, 14, 33] . However, predicting which patients will have a treatment failure on the basis of these parameters does not seem to be feasible.
Nevertheless, it has been seen that patients who can be successfully treated and those in whom treatment will be a failure can be easily predicted, and patients with a high turnover can be determined using UR values, which can be easily calculated by conducting a thyroid uptake test before the treatment. The RAI uptake test is widely used in GD both in the differential diagnosis of HT and to decide on the RAI treatment dose [34, 35] . However, in some centers, it is not preferred for diagnosis and treatment planning, as the patient incurs additional expenditure and additional time is required to conduct the test.
There are some studies in the literature that aimed to reduce the turnover rate and increase treatment success in HT patients. It has been shown that cold iodine or lithium administrations, together with RAI treatment, can be used to prolong the effective half life of RAI in the thyroid gland and increase the dose of radiation absorbed by the thyroid tissue [7, 13, [26] [27] [28] . However, there is no study that showed the effect of RIT combined with cold iodine or lithium application on treatment success in patients with a UR value of at least 1.
The most commonly preferred treatment option in patients in whom RAI treatment fails is a second dose of RAI. Treatment success rate was as high as 95% with this second dose of RAI, which is in congruence with that reported in the literature [19] .
Conclusion
The main purpose of RIT is to achieve optimum treatment success with a minimum RAI dose, which may be determined by a simple method. The UR may be used to predict the patients in whom therapy fails or succeeds. This practical index can be calculated using a pretreatment thyroid uptake test. The results of the present study showed that 10 mCi RAI is an ideal dose with an optimal treatment efficacy in GD patients with a UR value of less than 1. In contrast, 10 mCi was seen to be a dose that fails in efficiency in the case of a UR value of at least 1. Patients who have a UR value of at least 1 should be informed, before administration of RIT, that the treatment has a high chance of failure and that they may require a second dose. Further and more detailed studies need to be conducted to evaluate the efficiency of ablative dose applications and RIT combinations with medications like cold iodine or lithium, which aim to reduce the rate of RAI turnover.
